Roche's Boniva to get generic competition; Pfizer's arthritis treatment moves toward approval;

 @FiercePharma: Derek Lowe's take on the GSK-won't-buy-AstraZeneca story. Hint: Fig Newtons figure in. More | Follow @FiercePharma

 @EricPFierce: FDA says drugs shortages are down dramatically. Commissioner gives president credit. Really? Report | Follow @EricPFierce

> Indian genericsmaker Dr. Reddy's says it has received FDA approval to produce a knock-off of Roche's osteoporosis drug Boniva. Story

> The upside of Regeneron Pharmaceuticals' ($REGN) Arcalyst may not be enough to offset the risk of side effects, FDA staff reported today. Story

> Analysts are predicting Pfizer's ($PFE) experimental treatment for rheumatoid arthritis will get regulatory approval next week despite some significant risks. Story

> FDA orders Alexza Pharmaceuticals ($ALXA) to fix manufacturing issues before it will approve its NDA for Adasuve, a schizophrenic and bipolar disorder treatment. Story

> In a twist on the usual pharma deal, Affymetrix will actually pay $15 million less than its initial bid of $330 million in the buyout of eBionscience.  Story

Biotech News

 @FierceBiotech: Startup Bina Technologies tries Apple-like strategy in genomics field. Item | Follow @FierceBiotech

 @JohnCFierce: Big week for Pfizer coming up, with tofacitinib panel. They need a win here to regain some R&D cred. Story | Follow @JohnCFierce

 @RyanMFierce: Fumapharm AG shareholders take early payday on BG-12 interest in $761M Royalty Pharma deal. Release | Follow @RyanMFierce

 @MarkHFierce: Scientists have identified a gene linked to a rare condition where babies are born minus a spleen. Release | Follow @MarkHFierce

> Bill calls for cancer clinical trials results to be reported--or else. News

> FDA whacks Alexza Pharma with CRL for Adasuve. Story

> Pfizer faces crucial panel vote on blockbuster hopeful tofacitinib. Article

Medical Devices News

 @FierceMedDev: U.K. regulators toughen focus against counterfeit devices and drugs. More | Follow @FierceMedDev

> Qiagen snatches up maker of amniotic fluid detection test. News

> Retinal implants yield amazing results in U.K., China. More

> (Lack of) FDA device monitoring draws new scrutiny. Article

> U.K. regulators toughen focus against counterfeit devices and drugs. Story

And Finally... AstraZeneca's ($AZN) exiting CEO David Brennan may be a $65 million example of the Peter Principle, says the health blog. Post